MOLECULAR PARTNERS ADS/1 - Asset Resilience Ratio
MOLECULAR PARTNERS ADS/1 (6ML0) has an Asset Resilience Ratio of 10.19% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 6ML0 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how MOLECULAR PARTNERS ADS/1's Asset Resilience Ratio has changed over time. See 6ML0 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down MOLECULAR PARTNERS ADS/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of MOLECULAR PARTNERS ADS/1.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €10.40 Million | 10.19% |
| Total Liquid Assets | €10.40 Million | 10.19% |
Asset Resilience Insights
- Moderate Liquidity: MOLECULAR PARTNERS ADS/1 has 10.19% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
MOLECULAR PARTNERS ADS/1 Industry Peers by Asset Resilience Ratio
Compare MOLECULAR PARTNERS ADS/1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for MOLECULAR PARTNERS ADS/1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for MOLECULAR PARTNERS ADS/1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.19% | €10.40 Million ≈ $12.16 Million |
€102.11 Million ≈ $119.37 Million |
-43.78pp |
| 2024-12-31 | 53.97% | €85.56 Million ≈ $100.03 Million |
€158.53 Million ≈ $185.34 Million |
-6.31pp |
| 2023-12-31 | 60.29% | €119.58 Million ≈ $139.80 Million |
€198.35 Million ≈ $231.89 Million |
-1.18pp |
| 2022-12-31 | 61.47% | €161.20 Million ≈ $188.46 Million |
€262.26 Million ≈ $306.61 Million |
+26.14pp |
| 2021-12-31 | 35.33% | €61.00 Million ≈ $71.32 Million |
€172.67 Million ≈ $201.87 Million |
-- |
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more